WIN Consortium Announces 4th Win Symposium in Personalized Cancer Medicine, Paris, June 28-29, 2012
Posted: Friday, November 25, 2011
PARIS-(BUSINESS WIRE)
WIN Consortium, initiated by Cancer Institute Gustave Roussy (France) and University of Texas MD Anderson Cancer Center (USA), is proud to announce the 4th WIN Symposium in Personalized Cancer Medicine, to be held in Paris, France, June 28-29, 2012. This symposium will be the continuation of a highly successful series of annual meetings which provide a forum for discussion of the rapidly advancing field of personalized cancer medicine.
Building upon the success of the 3rd WIN Symposium, held in July 2011, the WIN Consortium has decided to continue this series by scheduling the 4th WIN Symposium in Personalized Cancer Medicine. Like the previous symposium, this Symposium will be held at Palais des Congrès in Paris. Membership of the Organizing Committee includes: John Mendelsohn (USA); Alexander Eggermont, (France); Richard L. Schilsky (USA); Vladimir Lazar (France), Gerald Batist (Canada); and Catherine Bresson (United Kingdom).
The main theme of the scientific program will be “Efficacy of biomarkers and personalized cancer therapeutics.” The provisional program features sessions on:
Fundamental concepts and strategies to improve efficacy of therapeutics;
Biology-driven diagnostics and therapeutics;
Combinatorial biomarkers and efficacy of therapeutics;
Innovative targets and new drug discovery;
Innovative therapeutics and clinical trials;
Systems Biology and bioinformatics;
WIN Consortium’s Global Innovative Clinical Trials
More detailed general information will be posted to the WIN Consortium website (www.winconsortium.org) shortly, or may be requested by sending an email to the WIN Symposium Secretariat (win@mccm.nl).
About the WIN Consortium
The WIN Consortium (www.winconsortium.org) is a joint initiative of Institut Gustave Roussy (France) and University of Texas - MD Anderson Cancer Center (USA) which brings together 17 cancer centers around the world, the National Breast Cancer Foundation, Sage Bionetworks and three technology partners: Agilent Technologies, GE Healthcare and Life Technologies. The mission of WIN is to conduct worldwide innovative clinical trials in order to accelerate the pace and to reduce the cost of translating effective cancer treatments to the patient. The WIN Consortium is chaired by John Mendelsohn, M.D., University of Texas - MD Anderson Cancer Center, and is based at Cancer Institute Gustave Roussy in Paris.
Contacts
WIN Consortium
Vladimir Lazar, Chief Operating Officer
vladimir.lazar@winconsortium.org
or
Catherine Bresson
Director Operational Team
catherine.bresson@winconsortium.org